Receptor‐mediated delivery of an antisense gene to human brain cancer cells
- 14 February 2002
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 4 (2) , 183-194
- https://doi.org/10.1002/jgm.255
Abstract
Background The goal of this work was the development of a gene targeting technology that will enable the delivery of therapeutic genes to brain cancer cells in vivo following intravenous administration. High‐grade brain gliomas overexpress the epidermal growth factor receptor (EGFR) and EGFR antisense gene therapy could reduce the growth of EGFR‐dependent gliomas. Methods A human EGFR antisense gene driven by the SV40 promoter in a non‐viral plasmid carrying elements that facilitate extra‐chromosomal replication was packaged in the interior of 85 nm pegylated immunoliposomes (PILs). The PILs were targeted to U87 human glioma cells with the 83‐14 murine monoclonal antibody (MAb) to the human insulin receptor (HIR). Results Confocal fluorescent microscopy demonstrated that the unconjugated HIR MAb is rapidly internalized by the glioma cells. Endocytosis followed by entry into the nucleus was also demonstrated for the HIR MAb conjugated PILs carrying fluorescein‐labeled plasmid DNA. The PILs delivered exogenous genes to virtually all cells in culture, based on β‐galactosidase histochemistry. The targeting of a luciferase gene to the U87 cells with the PILs resulted in luciferase levels in excess of 150 pg/mg protein after 72 h of incubation. The level of luciferase gene expression in the U87 cells achieved with the PIL gene targeting system was comparable to that with lipofectamine. Targeting the EGFR antisense gene to U87 glioma cells with the PILs resulted in more than 70% reduction in [3H]thymidine incorporation into the cells; this was paralleled by a 79% reduction in the level of immunoreactive EGFR. Conclusion The present work describes the targeting of an EGFR antisense gene to human brain cancer cells, which results in a 70–80% inhibition in cancer cell growth. PILs provide a new approach to gene targeting that is effective in vivo following intravenous administration without viral vectors. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Drug targeting, drug discovery, and brain drug developmentPublished by Cambridge University Press (CUP) ,2001
- Nuclear Accumulation of Exogenous DNA Fragments in Viable Cells Mediated by FGF-2 and DNA Release upon Cellular InjuryExperimental Cell Research, 2001
- Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trialsNature Medicine, 1999
- A γ34.5 mutant of herpes simplex 1 causes severe inflammation in the brainNeuroscience, 1998
- Loss of Binding and Entry of Liposome-DNA Complexes Decreases Transfection Efficiency in Differentiated Airway Epithelial CellsJournal of Biological Chemistry, 1997
- Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary GlioblastomasBrain Pathology, 1996
- Pharmacokinetics, Tissue Distribution, and Expression Efficiency of Plasmid [33P]DNA Following Intravenous Administration of DNA/Cationic Lipid Complexes in Mice: Use of a Novel Radionuclide ApproachJournal of Pharmaceutical Sciences, 1996
- Cis‐Element/Cytoplasmic Protein Interaction Within the 3′‐Untranslated Region of the GLUT1 Glucose Transporter mRNAJournal of Neurochemistry, 1996
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial originNature, 1985
- Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cellsNature, 1984